Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...

Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

Aflibercept 8 mg improved injection intervals in previously treated eyes with wet age-related macular degeneration while ...

Deploying lenacapavir will require rethinking who delivers HIV prevention, how it is financed, and what policy infrastructure ...

Biocon is introducing Bosaya (denosumab-kyqq), a biosimilar to Prolia, and Aukelso (denosumab-kyqq), a biosimilar to Xgeva.

Biocon Limited has announced the commercial launch of its denosumab biosimilars, Bosaya and Aukelso, in the United States, ...

Biocon makes US commercial launch of Bosaya and Aukelso, denosumab biosimilars: Our Bureau, Bengaluru Wednesday, April 8, 2026, 16:10 Hrs [IST] Biocon has made a commercial launch ...

Bosaya(TM) and Aukelso(TM) (both denosumab-kyqq products) now available in the United States, following U.S. FDA approval in September 2025 with an interchangeable designation -- Potential benefit to ...

Potential benefit to the estimated 10 million adults with osteoporosis and over 330,000 patients annually with bone ...

Biocon launches two FDA-approved interchangeable denosumab biosimilars in the US, targeting osteoporosis and bone metastasis in a $5B market.

Apotex Inc. ("Apotex" or the "Company"), the largest Canadian‑based global pharmaceutical company, today announced that Health Canada has approved DENOZA™ (denosumab injection), a biosimilar ...